Introduction 1
Gene dysfunction in disease is frequently studied through a systems biology framework (Kitano, 2002) in 2 which genes are linked through their shared functional properties and pathways. To assay the networks 3 underpinning a phenotype it is common to look to the transcriptome as a measure of the activity of the 4 genes in the system (Cookson et al., 2009; Dermitzakis, 2008; Jirtle and Skinner, 2007; Lamb et al., 5 2006) . Gene expression changes are detected through differential expression, and then systems-level 6 signals are determined through gene set enrichment (Hosack et al., 2003; Subramanian et al., 2005) , 7 network connectivity assessments (Barabási et al., 2010; Greene et al., 2015; Lage et al., 2007) , or gene 8
property enrichment (Kircher et al., 2014; Lek et al., 2016) . These methods all contextualize genes to 9 known biological properties, functions and pathways. As this step aims to summarize the disease 10 mechanism, it is typically the last step in an analysis, with little direct evaluation for efficacy (Nguyen et 11 al., 2016; Pham et al., 2017; Yu et al., 2017) . This reflects the challenge of developing a systematic 12 framework for doing so, particularly where normal heterogeneity of phenotype and genotype may 13 generate joint functional signals of their own. In this work, we seek to assess the replicability of disease 14 and systems biology signals using a meta-analytic approach that exploits multiple pedigrees of a rare 15 and homogeneous disorder, the TAF1 syndrome. 16
Genes may share signals for either biological or technical reasons. In gene or protein space, a "systems 17 biology analysis" is used to define or assess these shared signals, with the assumption that the main 18 driver behind the common features is biological (Draghici et al., 2007; Huang et al., 2008) . A systems 19 analysis can take the form of enrichment (e.g., Gene Ontology annotation overlaps) or more complex 20 methods (e.g., k-nearest neighbors in co-expression networks), but ultimately outputs pathway-level 21 summaries. Signals shared between genes due to technical properties such as sampling biases, 22
confounded study designs, and batch effects can arise as false positives in a systems biology analysis and 23 may be difficult to identify. False positive results can also easily arise due to unknown or uncontrolled 24 biological variation, stemming from difficulties in phenotyping and the genetic heterogeneity of complex 25
disorders (e.g., schizophrenia and autism (Purcell et al., 2014; Sanders et al., 2017) ). There, variation in 26 either phenotype or genotype may average away real disease effects and/or generate gene expression 27 variation unrelated to disease (Hansen et al., 2011) (Figure 1) . Replication is a central test of which of 28 the two -either disease specific or untargeted variation -has driven the appearance of a characteristic 29 signal across genes. In this work we assess the recurrence of candidate genes and pathways across 30 separately analyzed data-sets. We characterize the degree to which replicate transcriptional signatures 31 occur in groups of genes (e.g., co-expression) versus outliers (genes acting alone). A particular target of 32 our analysis is the TAF1 syndrome cohort, a rare and well-defined X-linked neurodevelopmental disorder 33 with multiple pedigrees for assessment (see Box 1 for further details). 34
We are able to look for replicability of disrupted gene expression signatures within the TAF1 cohort for 35 four main reasons: multiple pedigrees, phenotypic similarity, genetic homogeneity and a plausible 36 mechanism for an impact on expression levels. We describe four classes of signals that can be extracted 37 from disease analyses, reflecting whether signals are shared across families (recurrent/replicable) and 38 across functional sets of genes (joint/disjoint signals). In TAF1 syndrome, we find recurrence of gene 39 expression change at the gene-level for two plausible candidates, CACNA1I and IGFBP3. At the systems 40 biology level, we find little replicable enrichment, assessed via gene set enrichment of the Gene 41
Ontology (GO) and via co-expression. Interestingly, the strongest replicable signal appears to arise from 42 genes acting outside of the systems biology framework. We call genes meeting this property "functional 43 outliers". To see if our analysis is informative in other diseases and study designs, we also assess 1 common heterogeneous neurodegenerative and neuropsychiatric disorders in over a thousand samples 2 (~1.7k), including 5 Huntington's disease studies, 15 Parkinson's disease studies, and 10 schizophrenia 3 studies. Once we extend the analysis to the more heterogeneous brain disorders, we are able to 4 recapitulate known disease mechanisms, which appear as both recurrent joint signals (e.g., immune 5 signaling pathways in schizophrenia), and recurrent functional outliers (e.g., SNCA in Parkinson's). The 6 results from the four disorders studied here highlight the potentially important role of functional 7 outliers, and suggest caution in applying gene-set based methods, such as enrichment or co-expression, 8 in summarizing disease manifestation and mechanism. 9 10 11 12 Figure 1 What does a systems biology approach tell us? A systems biology assessment summarizes the properties 13 of genes that are captured in an experiment, but can highlight both true and false positive results. In some cases, 14 genes with a shared function are unlikely to arise in the experiment by chance. A gene set analysis will highlight 15 their shared function (top panel), but not their independent value in identifying the enriched function. In other 16 cases, a set of genes are so closely related both technically and biologically that if one arises, the others are almost 17 certain to do so. A statistical analysis treating the genes as independent (bottom panel) will attach a misleading 18 significance to the shared presence of the genes. These genes and gene sets will be unlikely to replicate in future 19 studies. To probe in detail the functional gene signals that recur significantly due to disease, we focus a large part of our 2 analysis on TAF1 syndrome also known as "X-linked syndromic mental retardation-33" (MRXS33 MIM# 300966 3 (O'Rawe et al., 2015) ), an X-linked recessive neurodevelopmental disorder. TAF1 syndrome is a rare, penetrant, 4 and overall homogeneous disorder with no known disease mechanism. Genetically, it is defined by mutations in 5 TAF1 (TATA-Box Binding Protein Associated Factor 1), a key subunit of the general transcription factor TFIID 6 (Louder et al., 2016; Müller et al., 2010) . TFIID promotes transcriptional initiation by binding to the core promoters 7 of genes, and recruits other transcription factor subunits that act as co-activators or co-repressors, encoding 8 regulatory specificity (Pijnappel et al., 2013) . Other subunits of TFIID are candidate genes in developmental and 9 neurodegenerative diseases (Alazami et al., 2015; Bauer et al., 2004; El-Saafin et al., 2018; Hellman-Aharony et al., 10 2013), with reduced binding between the subunits playing a role in the pathogenesis. The characteristic 11 phenotypic features of the TAF1 disorder include global developmental delay, facial dysmorphology, generalized 12 hypotonia, hearing impairments, microcephaly, and a characteristic gluteal crease with a sacral caudal remnant. All 13 documented cases of the disorder affect males, and mostly have arisen de novo. In the few known inherited cases, 14 female carriers do not show any features of the disease. This is generally a feature of X-linked disorders, with 15 extreme X-skewed inactivation playing a role in phenotypic variation and protection in females (Migeon, 2007) .
16
Despite being a relatively rare disorder, we have access to multiple pedigrees. In this study, six families were 17 recruited from around the world, mainly of European descent and were between 5-21 years of age. All probands 18 have point mutations in their TAF1 transcription factor, except for a single CNV case. In three of the pedigrees, the 19 mothers are carriers of the same mutation.
20
The four properties -global transcriptional impact, characteristic phenotype, genetic homogeneity, and multiple 21 pedigrees -allow us to perform a disease replicability analysis using easily accessible blood transcriptional profiles.
22
We can study each pedigree as a separate differential expression experiment: identifying differentially expressed 23 genes and overrepresented pathways and then assessing these candidate genes and pathways for recurrence 24 across pedigrees.
25

Results
26
Replicability design overview 27
To understand shared disease signals, we assess replicability by testing the recurrence of candidate 28 genes and pathways across separately analyzed differential expression experiments. We classify 29
whether signals are replicated across families or datasets (and call this "recurrent") and whether the 30 signals involve sets of genes acting together (and call this "joint"). For the TAF1 syndrome cohort 31 analysis, we performed a family-based differential expression analysis, then tested for gene-level and 32 pathway-level signals through gene set enrichment and a co-expression network modularity analysis 33 (Figure 2A) . We then looked across the pedigrees to evaluate where signals arise, summarized in Figure  34 2B. There are four possibilities we can assess. 1) We may have a joint functional signal, where many 35 genes are part of the same set/module, and it is this module which is replicated across families (i.e., 36 recurrent and co-functional). 2) We may have a recurrent disjoint signal: genes that replicate across 37 families, but do not share common functions with other genes (i.e., recurrent functional outliers). 3) 38
There is also the chance of a non-recurrent but joint signal: genes contribute to a shared signal, but 39
uniquely within a family. 4) And finally, there is also an entirely disjoint signal, where we see one-off 40 genes that are most likely false positives. We test all possible outcomes by measuring recurrence of 41 genes, gene set enrichment and co-expression modularity (Figure 2C) . We go through the results in the 42 following sections. respectively). We test for joint functional properties through gene set enrichment and co-expression modularity. 4 (B) Given multiple pedigrees/families of the disorder, we can piece together whether disease signals are recurrent 5 across families or non-recurrent, and due to multiple genes (joint) or independent genes (disjoint). (C) This can be 6 done by assessing recurrence at the gene and pathway levels. (D) The TAF1 syndrome cohort pedigrees used in this 7 analysis. Four cases have missense mutations, one case a splice site mutation, and the last case a CNV duplication.
8
Three of the mothers are carriers with no distinguishing characteristics.
1
Since TAF1 is a transcription factor, we first wished to see if there was a common disease signature at 2 the expression level. We identified differentially expressed genes (DEGs) using a family-based 3 differential expression (DE) analysis (see STAR Methods). We saw only moderate overlaps of the 4 differentially expressed genes between each of the pedigrees tested ( Figure 3A) for both upregulated 5
and downregulated genes. There were at most 26 (out of 100) genes in common between Family 3 and 6
Family 5 (Figure 3B , p~1e-40). Even though few genes overlapped when assessed pairwise, there were a 7 number of differentially expressed genes that were recurrently DE across families (significant if in at 8 least three families FDR<0.05), with a modest number significantly recurrent. We find four genes 9
recurrently upregulated (ISG15, RN7SK, FFAR3 and IGLV1-44), and 14 downregulated (C1QA, CFH, RPS7, 10 SNRPG, LSM3, RPS3A, IGFBP3, RPL7, KLRB1, OLFM4, PRSS30P, KIR2DS4, S100B and CACNA1I Figure 3C , 11
see Table S4 ). These results suggest that even though a large fraction of the differentially expressed 12
genes are unique to each pedigree, a recurrent gene transcriptional disease signature is present within 13 the data. To test the dependence of these results on the DE threshold (top 100 genes), we repeated the 14 recurrence using different DE thresholds ( Figure 3D ). As the change in the number of the DEGs called 15
had an influence on the significance of recurrence, we see peaks and troughs of gene recurrence 16
corresponding to the change in adjusted p-values. We found similar numbers of significantly recurrent 17 genes within these ranges, with cut-offs between 50 and 200 genes most informative. We use the top 18
100 DEGs for the remainder of the analyses. 
12 1
While only a modest number of genes overlapped across the pedigrees, it is possible that non-recurrent 2 genes still provide a shared disease signal, with variability in the exact genes identified due to technical 3 limitations. To assess this possibility, we perform gene set enrichment in two ways. First, we test 4 differentially expressed gene lists from each pedigree independently, and then measure the recurrence 5 of the enriched pathways across the studies, as a parallel to the gene recurrence assessment. We then 6 check for significantly recurrent pathways. Second, we test for enrichment of the recurrent genes 7 themselves. We performed gene set enrichment using a subset of the Gene Ontology (GO slim) and 8
found few pathways significantly enriched on a per family basis (FDR<0.05, Figure 4A ), with the 9 exception of Family 5, which had 22 downregulated pathways. Then, to assess the disease significance 10 of the enrichment signal, we calculated the similarity and significance of recurrence of these pathways 11
across the families. As in the case of gene recurrence, we expect the disease signal (here the enrichment 12 signal) to replicate across the cohort if it is disease linked. Of the significantly enriched pathways, at 13 most three were significantly upregulated and recurrent across the families ( Figure 4B and Table S5 ).
14
The pathways significantly recurrent were larger than average, implying broad properties (e.g.,
15
GO:0002376 immune system process, GO:0006950 response to stress and GO:0007165 signal 16 transduction, Figure S3A ) with different genes contributing to the enrichment within each of the 17 families ( Figure 4C ). While pathways were significantly recurrent across family-specific upregulated 18
genes, the few recurrent upregulated genes do not show enrichment. In contrast, we found no 19 downregulated pathways as significantly recurrent (Figure 4D ) despite the gene recurrence and family-20 specific enrichment. However, the recurrent downregulated genes themselves ( Figure 4E ) are enriched 21
for six GO groups related to ribosomal functions, including RNA binding, translation, and protein 22
targeting. The discrepancy between the pathways enriched with the recurrent genes and the pathways 23 significantly recurrent suggests that the weak enrichment signals are not specific to the disorder. for the upregulated genes. Each column is a gene, and each row a family. The colored bars below highlight the GO 5 terms that these genes belong to. The signal associated with the recurrent GO terms is distributed across different 6 genes, shown by low overlap across the families. (D) There are no significantly recurrent pathways with the 7 downregulated genes. (E) However, the recurrent genes themselves are enriched for ribosomal pathways (p-Top recurrent genes do not appear to act within a systems biology framework 1
As we are limited by gene set annotations, the weak enrichment may be due to our lack of complete 2 pathway knowledge (Thomas, 2017) . Therefore, to test for joint signal with a different but 3 comprehensive data modality, we looked to co-expression. Genes that are co-expressed are known to 4
share functions, are co-regulated, or are parts of known pathways (Gaiteri et al., 2014) . Unlike most 5 curated or inferred gene annotations, co-expression can be assessed genome-wide. We used the gene 6 pair co-expression frequency from a wide corpus of data (external to this study) as our co-functionality 7 measure (see STAR Methods). For each family's set of differentially expressed genes, we found gene co-8 expression blocks comprising more than two thirds of these genes (Figure S4A ). We show an example of 9 this for the top 100 down-regulated genes from Family 1 in Figure 5A . 10
We then asked where the recurrent genes sit in relation to the co-expression modules. Interestingly, we 11 found the outlier or disjoint genes (those not in the large modules) were frequently among the most 12 recurrent genes across the families (Figure 5B) . Almost a third of the disease signature was not within 13 common co-expression or functions, but rather appeared within very small modules or as outliers. For 14 functional characterization to usefully summarize the DE list, candidate genes should be enriched within 15
pathways. This was not true of TAF1 disorder candidate genes. In particular, we find that the top 16
downregulated genes CACNA1I and IGFBP3 are not within modules. Once we perform a gene set 17 enrichment analysis on the genes excluding those in modules, nearly all of the enrichment signal is lost, 18
highlighting that the most recurrent candidates act outside of a common joint signal. If this is similarly 19 true of the disease mechanism, then a systems-style analysis will fail to discover the disease signal. 
8
(B) The significantly recurrent genes can be divided into those present within co-expression modules (joint) and 9 those not (disjoint). The genes in bold are the functional outliers and the venn diagrams summarizes the number of 10 genes in each category. (C) If we look at the enrichment of these DE gene sets (pre-filtering dark line +/-SD 11 shadow), we see that filtering off the modules removes all but a few significant terms (lighter line, +/-SD shadow).
13 1
The TAF1 cohort is interesting in part for being a rare disorder with a penetrant and distinct phenotype. 2
In order to assess the role of functional outliers more broadly, we looked to three other disorders with 3 substantial transcriptomic data and varying degrees of genetic heterogeneity. We focused on 4
Huntington's disease (HD), Parkinson's disease (PD), and schizophrenia (SCZ). All studies used are listed 5
in Table S3 . 6
Huntington's disease is an inherited neurodegenerative disorder, characterized by the progressive 7 degeneration of cells in the brain (primarily the striatum) and is associated with impaired movements, 8 decline in cognitive abilities and depression (Bates et al., 2015) . Similar to TAF1 syndrome, HD is a 9 monogenic disorder. The disease is caused by an expansion of the CAG repeats in the Huntingtin gene 10 (HTT), which is believed to be toxic to other proteins once mutated. The exact functions of HTT are still 11
unclear, along with the mechanisms (Bates, 2005) . To test the possibility of a joint functional signal, we 12
assessed five expression studies of HD, following the evaluative approach we took with the TAF1 cohort. 13
Interestingly, we found both joint and disjoint signals ( Figure 6A) . A total of 18 upregulated genes were 14 significantly recurrent, with ANGPT1 (Angiopoietin 1) recurrent in four of the five studies. This gene 15
plays an important role in vascular development and angiogenesis. Along with other recurrent genes, 16
such as ANG (angiogenin), KCNE4 and SLC14A1, there seems to be an associated cardiovascular 17
phenotype. Heart disease is comorbid with Huntington's, and these gene candidates suggest a link to 18 cardiac development. Additionally, we found six genes recurrently downregulated in at least three of the 19 five studies; these include synaptic genes (SV2C, NRGN, and HTR2C) and a calcium channel related to 20 modulation of firing in neurons (CACNA1E). We found that all the recurrent downregulated genes were 21 part of modules, thus showing a strong joint functional signal. And in the upregulated genes, ANG is a 22
functional outlier, while all of the other recurrent genes were in shared functions. These results suggest 23 a stronger joint functional signal than in the TAF1 disorder. All recurrent genes are listed in Table S6 . 24
Parkinson's disease is a progressive neurodegenerative disorder, characterized by the loss of 25 dopaminergic neurons leading to decreased motor function. Unlike the TAF1 cohort, Parkinson's has 26 multiple genes implicated, each with different onset stages (e.g., LRRK, SNCA, PRKN, FBXO7, PARK7, and 27 PINK1) (Poewe et al., 2017) , increasing the genetic heterogeneity of the disorder and data. We collected 28 15 differential expression gene lists and repeated our analysis. We find a subset of significantly recurrent 29 downregulated genes but no upregulated genes as significant ( Figure 6B) but the joint signal was less predominate than in Huntington's disease. All recurrent genes are listed in 40 Table S7 and enriched pathways in Table S8 . 41
Our final use case was on schizophrenia, a neuropsychiatric disorder characterized by abnormal social 42
behavior and psychosis, along with other cognitive impairments (Kahn et al., 2015) . The disorder has 43 strong environmental and genetic components (Gejman et al., 2010; Rees et al., 2015) , with many genes 44 increasing risk. The risk alleles are also shared amongst many other neuropsychiatric phenotypes, 45 making this a hard disorder to classify both genetically and phenotypically, and thus difficult to 1 characterize molecularly. We assessed 10 disease expression studies and found both up-and 2 downregulated transcriptional signatures (Figure 6C ), but these recurred in three or four studies at 3 most. Consistent with the genetic and phenotypic heterogeneity of the disorder, we find that recurrent 4 genes have both joint and disjoint signals. Of the genes upregulated, we find recurrence of the FCN3 5 gene (Ficolin 3), a recognition molecule in the lectin pathway of the complement system (Garred et al., 6 2009; Mayilyan, 2012) . This is of interest in schizophrenia as it potentially interacts with C4, a known risk 7
allele (Sekar et al., 2016) . The remaining recurrent genes were enriched for an inflammatory signature, 8 also recapitulating known schizophrenia etiology. Among recurrent downregulated genes is the protein 9
phosphatase inhibitor PPP1R17 which is primarily expressed in Purkinje cells in the cortex of the 10 cerebellum, a brain region which may play a role in the disorder (Maloku et al., 2010) . Interestingly, both 11
FCN3 and PPP1R17 were functional outliers, with the other recurrent genes showing joint functional 12 signals. All recurrent genes are listed in Table S9 and enriched pathways in Table S10 . Overall, across all 13 the disorders, the joint signals via co-expression were much stronger than in the TAF1 syndrome cohort, 14
but there were important functional outlier candidates within each disease. The main contribution of this work is a rigorous analysis of replicability of functional signals implicated in 2 disease through expression analysis. We describe four classes of signals that can be extracted from 3 disease analyses, reflecting whether signals are shared across families or studies (recurrent) and/or 4 across functional sets of genes (joint). These are: 1) recurrent joint signals, 2) recurrent but disjoint, 3) 5 joint but not recurrent 4) not recurrent and disjoint. Our evaluation of the rare TAF1 syndrome and 6 three common disorders highlighted an important feature of disease that has been overlooked in the 7 systems paradigm: the role of functional outliers, classified as recurrent but with no joint or shared 8 function. 9
In the TAF1 cohort, we believe that the recurrent disjoint genes are the disease signal for reasons within 10 and outside the present analysis. Of the candidates we found, CACNA1I and IGFBP3 had the strongest 11 recurrent signal. CACNA1I is a calcium channel subunit, and mutations in calcium channels are known to 12
have similar phenotypes to the cohort here, including intellectual disability, autism and dystonia (Fukai 13 et al., 2016; Lu et al., 2012) . In addition, there is a TAF1 binding site upstream of the gene (Wang et al., 14 2012). Most convincing is that this gene has been implicated recurrently in other brain disorders; it is 15 the only recurrent missense de novo in schizophrenia studies (Gulsuner et al., 2013) , one of the few 16
overlapping candidates between schizophrenia and autism. The other recurrent candidate was the 17
insulin-like growth factor-binding protein 3 (IGFBP3). Downregulation of this gene has been recently 18 implicated in a developmental disorder with a behavioral and cognitive phenotype (Perez et al., 2018) .
19
Despite these fairly convincing properties, it remains to be seen whether the candidate genes are 20 specific to the TAF1 cohort, or rather might reflect a more general signature of developmental disorders. 21
Consistent with the view that functional outliers and aberrantly expressed genes may play a particularly 22 strong role in diseases with rare genotypic variation, we do not find them as the strongest signal in the 23 other disorders. In our meta-analysis, we focused on disorders with varying genetic architecture and 24 those also well powered for assessment. In each case, the meta-analysis was powered to call individual 25 genes as recurrent, identifying both known and novel candidate disease genes. This was not dramatically 26 more than those found assessing across individual families within the TAF1 cohort, most likely due to 27 the heterogeneity of the other disorders or their study designs. Within each disorder, we observed clear 28 joint functional signals present through the co-expression analysis, but to varying degrees (e.g., strong 29
immune signals in schizophrenia). Interestingly, despite the greater role of joint functional signals within 30 these disorders, plausible functional outliers exist for each, most notably in the case of Parkinson's 31 disease where known disease genes, such as SNCA, appear to be acting outside of their typical behavior 32
as evaluated from co-expression. 33
Characterizing whether or not genes exhibit expected shared behavior bears strongly on the subject of 34 disease mechanisms. In the transcriptomic analysis of rare disorders, a joint disruption is almost always 35 assumed for disease. Yet, there is potential for unbuffered and uncharacteristic expression changes in a 36 few single genes, particularly when the assumed pathogenic variant is regulatory or the disorder is 37
monogenic (Cummings et al., 2017; Fresard et al., 2018; Kremer et al., 2017) . In this case, genes that are 38
no longer under regulatory control, or those that have gained regulation, will act out of place (Zeng et 39 al., 2015; Zhao et al., 2016) . These genes could be far downstream in a pathway or cascade, and thus not 40 impact other pathway members directly or immediately. In general, enrichment and other systems 41 biology analyses will miss these single genes that serve as unique bottlenecks. Our results suggest that 42 filtering based on enrichment will systematically remove interesting candidates. This does not mean that 1 systems-style analyses should not be conducted, rather we suggest that they be treated as a tool to 2 classify which genes are operating within a group and which are not. With time, strong candidates in 3 either category may be identifiable and provide valuable and distinct information about disease 4 mechanisms. 5 6 Acknowledgments 7
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(B) Given multiple pedigrees/families of the disorder, we can piece together whether disease signals are recurrent 13 across families or non-recurrent, and due to multiple genes (joint) or independent genes (disjoint). (C) This can be 14 done by assessing recurrence at the gene and pathway levels. (D) The TAF1 syndrome cohort pedigrees used in this 15 analysis. Four cases have missense mutations, one case a splice site mutation, and the last case a CNV duplication.
16
Three of the mothers are carriers with no distinguishing characteristics. Further information and requests for resources should be directed to and will be fulfilled by the Lead 3
Contact, Jesse Gillis (jgillis@cshl.edu). 4
EXPERIMENTAL MODEL AND SUBJECT DETAILS 5
The TAF1 syndrome cohort 6
We assessed 6 pedigrees of a genetically and phenotypically homogeneous X-linked TAF1 syndrome 7
cohorts. The original cohort was assembled by O'Rawe et al. (O'Rawe et al., 2015) , which included 11 8 pedigrees from around the world. The probands are male, between 5-21 years of age, have intellectual 9 disability, distinct facial dysmorphology, general hypotonia, hearing impairments, and a characteristic 10 intergluteal crease. Of the 6 pedigrees we studied, all probands had a point mutation in their TAF1 11 transcription factor, except for a single CNV case with a duplication of a ~0.42 Mb region at Xq13.1 that 12
includes TAF1 and other genes. 13
METHOD DETAILS
14
RNA-sequencing and processing 15
Blood was collected in PAXgene Blood RNA tubes and the RNA was isolated with the PAXgene Blood 16
RNA kit (QIAGEN) according to the manufacturer's recommendations. The RNA was quantified using 17
NanoDrop. To increase downstream sensitivity, globin mRNA was depleted from the samples using the 18
GLOBINclear Kit (Life Technologies). Briefly, RNA was precipitated with ammonium acetate, washed and 19 resuspended in 14 µl TE (10 mM Tris-HCl pH 8, 1 mM EDTA). Subsequently, for each sample 1.1 µg RNA 20
were hybridized with the provided streptavidin beads and purified. To control for variation in RNA 21 expression data, 1 µl of a 1:100 dilution of ERCC RNA Spike-In control (Thermo Fisher) was added to 1 µg 22
RNA and libraries generated according to the TruSeq Stranded mRNA Library Kit-v2 (Illumina) with the 23 index primers as indicated in 24 Table S1 . Quality control of the generated libraries was performed on a Bioanalyzer High Sensitivity DNA 25 chip (Agilent) and the concentration was measured using Qubit dsDNA HS Assay (Life Technologies). To 26 eliminate primer dimers in the libraries, additional purifications were performed using the Agencourt 27
AMPure XP system (Beckman Coulter). The libraries were pooled to 2-10 nM total concentration and 28 sequenced on an Illumina NextSeq 500, PE100, mid output. Libraries were generated independently for 29 each family and family-pools multiplexed and sequenced on separate lanes. ERCC spike-ins included in 30 the preparation were not used for normalization, but rather as a measure of quality control. Families 2, 31
3 and 4 showed the lowest variation in the ERCCs between family members, while family 5 and 6 had 32
higher technical noise (Figure S2) . Reads were filtered for QC and artifacts using the fastX toolbox, and 33 then the reads were paired up using an adapted python script 34
(https://github.com/enormandeau/Scripts/blob/master/fastqCombinePairedEnd.py). The reads were 35
aligned to the genome (GRCh38, GENCODE v22 (Harrow et al., 2012) ) using STAR (2.4.2a) (Dobin et al., 36 2012) . 37
Differential expression analysis 38
We calculated fold change between parents and probands for the differential expression analysis. We 39 first calculated the CPM (counts per million) for each individual, and then took the average CPM for the 40 parents and compared it the CPM of the proband. Fold change was defined as the log2 of the ratio of 41 25 these values after adding a pseudocount of 1. We exploited within-family variance to detect noisy 1 genes, removing genes that showed strong differential expression between the parents (i.e., top 100 up-2 regulated and top 100 down-regulated genes). After removing these highly variable genes, top up-and 3 down-regulated genes were defined based on ranked fold change. We assessed each family in a 4 separate batch (library preparation and sequencing run), holding technical variation constant in each 5
family and independent across families, so that gene-level recurrence is not expected to differ from the 6 null. By way of analogy, our experimental design resembles the analysis of de novo variants in DNA 7
analyses, in which as many factors as possible are held constant in the control group for the proband. 8
The use of unaffected family members as controls provides the closest possible genetic and 9 environmental match for the probands, constraining variability of known importance for expression 10 analysis (Raser and O'Shea, 2005) . Although each family-specific analysis is confounded with age and sex, 11
we anticipate that genes detected as differentially expressed that are due to these overlaps can be 12
assessed and identified directly, as these are well-powered properties in many previous studies. 13
Common co-expression frequency network 14
Human RNA-seq expression data was downloaded from Gemma (Zoubarev et al., 2012) . From the total 15
collection of approximately 300 human experiments, we selected 75 expression experiments (3,653 16 samples) that we could ascertain derived from tissues and not cell lines (listed in Table S2 ). For each 17 experiment, we consolidated our list of genes/transcripts to the ~30K genes with Entrez gene identifiers, 18
and did not limit either expression level or occurrence of expression. For each experiment with at least 19 10 samples, we generated a co-expression network by calculating Spearman's correlation coefficients 20
between every gene pair (Ballouz et al., 2015) and calculated the frequency that a pair of genes was 21 positively co-expressed (Spearman's correlation coefficient r s>0). We used this tally network as a 22
measure of the frequency of common co-expression of the gene pairs. The more observations with a 23 positive correlation, the more commonly co-expressed the pairs are (see Figure S1 ). 24
Gene set enrichment 25
To calculate gene set enrichment of the differentially expressed genes, we used an in-house gene set 26 enrichment R script based on the hypergeometric test. For each gene set, we calculated the significance 27 of the overlap of the differentially expressed genes with that set, correcting for multiple tests with 28
Benjamini-Hochberg (FDR, p.adjust in R). We used an in-house parsed version of GO (downloaded July 29 2015). We report GO slim (filtered to 132 GO groups) results primarily in the text but also assess a 30 subset of GO based on gene set size to remove redundancy (10-100 genes per group, 4605 GO terms). In 31 addition, we assess enrichment using four gene set lists from MSigDB (v6, 1127 gene sets, HALLMARK, 32
KEGG, REACTOME and BIOCARTA). 33
Co-expression module and outlier detection 34
In a set of differentially expressed genes, we defined co-expression modules as highly co-expressed 35 genes, seen as blocks in a co-expression network when clustered and represented as a matrix. Genes 36 that did not cluster or clustered weakly were considered outliers. These genes potentially have stronger 37
co-expression links with other genes outside of the gene set, but are not as well-linked within the 38 subset. To identify these two classes in our list of differentially expressed genes (DEGs), we first 39 extracted the sub-network of the differentially expressed genes from the co-expression frequency 40
network. Then, thresholding on the median co-expression value of the co-expression network, we used 41 this binary network as distance matrix, and performed hierarchical clustering of the genes. This 42 clustering returned a dendrogram of genes that are closer in distance, and we used this dendrogram to 43 define modules within the data. We used the R dynamicTreeCut (Langfelder et al., 2008) package to 1 select modules within the data with a cut height 0.995. We used these clusters to define our co-2 expression modules, where clusters with more than five genes were labelled as modules and those 3 smaller as co-expression outliers. 4
Recurrence analysis 5
To test for replicability of the disease signal, we measured differentially expressed gene recurrences and 6 the significance of recurrence as the probability of observing the differentially expressed genes across all 7 the pedigrees. We first calculated the significance of the pairwise overlap between families using 8
Fisher's exact test (phyper in R). We calculated the significance of recurrence of the differentially 9
expressed genes using the binomial test (pbinom in R), and then corrected for multiple tests using 10
Benjamini-Hochberg (FDR, p.adjust in R). After we filter on differentially expressed genes within 11 modules, we recalculate the significance of recurrence, this time with a permutation test to obtain an 12
FDR. Similarly, we use a permutation test to calculate significance of recurrence of the pathways from 13 the gene set enrichment assessment. 14
Meta-analysis datasets of neurodegenerative and neuropsychiatric disorders 15
We sought to repeat the systems biology evaluations in other disorders. We collected the reported 16 differentially expressed genes in Parkinson's disease, Huntington's disease and schizophrenia studies. 17
The majority of the studies were collected from recent review articles (Genevie et al., 2018; Li and Teng, 18 2015) , and from a search within the Gemma (Zoubarev et al., 2012) database for "parkinson's disease", 19
"huntington's disease" and "schizophrenia", respectively (listed in Table S3 ). We downloaded fold 20 changes, p-values and adjusted p-values. We removed studies from our analysis where we either could 21 not assess the direction of the differential expression and where no genes passed significance based on 22 log2 fold changes (log2FC|>1) and adjusted P-values (q<0.05). 23
QUANTIFICATION AND STATISTICAL ANALYSIS
24
All statistical analyses were done in R. Significance was defined as an FDR of 0.05 for all statistical tests. 25
DATA AND SOFTWARE AVAILABILITY
26
All R code, scripts and network data is available for download from our github repository 27 (https://github.com/sarbal/redBlocks). The RNA-seq data has been deposited in GEO/SRA under 28 accession number GSE84891. All other software used in this analysis is freely available and has been 29 listed in the key resources table. 
